The notable decrease in in vivo activity of venetoclax compared with navitoclax against the pediatric ALL PDX models suggests a reduced dependency of pediatric ALL on BCL2 compared with, for example, CLL (Ashkenazi, Fairbrother, Leverson, & Souers, 2017; Roberts, 2020). Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.